Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Gets Nasdaq Delisting Warning

NEW YORK (GenomeWeb) – Biocept's stock faces a potential delisting from the Nasdaq due to a failure to comply with the minimum bid price requirement, the company said in a filing made yesterday with the US Securities and Exchange Commission.

Biocept received a notice from Nasdaq stating that it had failed to maintain a required minimum closing bid price of at least $1 per share.

In order to regain compliance, Biocept must now maintain a minimum closing bid price for its common stock of at least $1 per share for at least 10 consecutive business days during a 180-day grace period. Biocept said it considering options available to it to achieve this goal.

In Monday morning trade, shares of Biocept were unchanged from Friday's close of $.81.